AbbVie and Gilgamesh Pharmaceuticals announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie’s expertise in psychiatry and Gilgamesh’s innovative research platform to discover novel neuroplastogens. Next-generation versions known as neuroplastogens target mechanisms that have shown potential to provide significant clinical benefits and are designed to minimize the challenging effects seen with first-generation compounds. Gilgamesh has leveraged a research platform to identify lead compounds in this novel class of therapeutics. AbbVie and Gilgamesh have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders. Upon exercise of the option, AbbVie will lead development and commercialization activities. Gilgamesh will receive an upfront payment of $65M from AbbVie and is eligible to receive up to $1.95B in aggregate option fees and milestones, as well as tiered royalties from mid-single to low-double digits on net sales.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Genmab reports Q1 revenue increased 46% vs. last year
- AbbVie price target lowered to $180 from $195 at BMO Capital
- AbbVie price target lowered to $191 from $196 at Morgan Stanley
- AbbVie price target lowered to $187 from $195 at Barclays
- AbbVie (NYSE:ABBV) Sinks as Humira Drug Sees Increased Competition